non-holder here doing some DD: anyone has thoughts on the Ph 2 efficacy data for proteinuria comparing to the CSL Vifor data for sparsentan? DMX200 looks inferior to me and if sparsentan had issues meeting the primary endpoint in a Ph 3 why would DMX200 succeed?
non-holder here doing some DD: anyone has thoughts on the Ph 2...
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
33.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $184.1M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5015 | 34.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.5¢ | 62123 | 4 |
View Market Depth
| Last trade - 09.48am 16/05/2024 (20 minute delay) ? |
| DXB (ASX) Chart |
Day chart unavailable